MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.97−0.08 (-3.90%)
Close on Nov 18, 2026Market cap $125.49MP/E –Yield –
MacroGenics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
MacroGenics's revenue for the twelve months ending Jun 30, 2026 was $167.67M, up 11.7% year over year. For fiscal 2025 it was $149.50M, down 0.3% from the year before. Over ten years it grew 4.0% a year on average. The highest annual figure on record is $157.74M in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.50M | -0.3% |
| FY2024 | Dec 31, 2024 | $149.96M | +155.3% |
| FY2023 | Dec 31, 2023 | $58.75M | -61.3% |
| FY2022 | Dec 31, 2022 | $151.94M | +96.2% |
| FY2021 | Dec 31, 2021 | $77.45M | -26.2% |
| FY2020 | Dec 31, 2020 | $104.88M | +63.4% |
| FY2019 | Dec 31, 2019 | $64.19M | +6.8% |
| FY2018 | Dec 31, 2018 | $60.12M | -61.9% |
| FY2017 | Dec 31, 2017 | $157.74M | +71.7% |
| FY2016 | Dec 31, 2016 | $91.88M | -8.9% |
| FY2015 | Dec 31, 2015 | $100.85M | +111.0% |
| FY2014 | Dec 31, 2014 | $47.80M | -17.6% |
| FY2013 | Dec 31, 2013 | $58.04M | -9.1% |
| FY2012 | Dec 31, 2012 | $63.83M | +11.6% |
| FY2011 | Dec 31, 2011 | $57.21M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $32.83M | +378.0% |
| Q1 FY2026 | Mar 31, 2026 | $20.78M | +57.5% |
| Q4 FY2025 | Dec 31, 2025 | $41.23M | +113.0% |
| Q3 FY2025 | Sep 30, 2025 | $72.84M | -34.2% |
| Q2 FY2025 | Jun 30, 2025 | $6.87M | -36.4% |
| Q1 FY2025 | Mar 31, 2025 | $13.19M | +44.9% |
| Q4 FY2024 | Dec 31, 2024 | $19.35M | +80.5% |
| Q3 FY2024 | Sep 30, 2024 | $110.71M | +964.8% |
| Q2 FY2024 | Jun 30, 2024 | $10.80M | -17.8% |
| Q1 FY2024 | Mar 31, 2024 | $9.10M | -62.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.72M | -85.3% |
| Q3 FY2023 | Sep 30, 2023 | $10.40M | -75.1% |
| Q2 FY2023 | Jun 30, 2023 | $13.14M | -49.5% |
| Q1 FY2023 | Mar 31, 2023 | $24.50M | +120.7% |
| Q4 FY2022 | Dec 31, 2022 | $73.10M | +416.7% |
| Q3 FY2022 | Sep 30, 2022 | $41.73M | +166.5% |
| Q2 FY2022 | Jun 30, 2022 | $26.01M | -15.4% |
| Q1 FY2022 | Mar 31, 2022 | $11.10M | -34.2% |
| Q4 FY2021 | Dec 31, 2021 | $14.15M | -73.2% |
| Q3 FY2021 | Sep 30, 2021 | $15.66M | -14.2% |
| Q2 FY2021 | Jun 30, 2021 | $30.76M | +51.8% |
| Q1 FY2021 | Mar 31, 2021 | $16.88M | +23.4% |
| Q4 FY2020 | Dec 31, 2020 | $52.69M | +109.2% |
| Q3 FY2020 | Sep 30, 2020 | $18.25M | -2.6% |
| Q2 FY2020 | Jun 30, 2020 | $20.26M | +91.2% |
| Q1 FY2020 | Mar 31, 2020 | $13.68M | +41.6% |
| Q4 FY2019 | Dec 31, 2019 | $25.19M | +59.5% |
| Q3 FY2019 | Sep 30, 2019 | $18.74M | -9.9% |
| Q2 FY2019 | Jun 30, 2019 | $10.59M | -43.8% |
| Q1 FY2019 | Mar 31, 2019 | $9.66M | +105.8% |
| Q4 FY2018 | Dec 31, 2018 | $15.79M | -89.6% |
| Q3 FY2018 | Sep 30, 2018 | $20.80M | +1150.6% |
| Q2 FY2018 | Jun 30, 2018 | $18.83M | +1030.5% |
| Q1 FY2018 | Mar 31, 2018 | $4.70M | +128.5% |
| Q4 FY2017 | Dec 31, 2017 | $152.36M | +2883.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.66M | -48.9% |
| Q2 FY2017 | Jun 30, 2017 | $1.67M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.11M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.26M | – |
See a number that looks wrong?